Safety and Efficacy Study of RP4010, in Patients With Relapsed or Refractory Lymphomas

Safety: Treatment-Emergent Adverse Events (AE); Treatment related AE, Serious Adverse Events
(SAE) and Clinical significant AE; Dose Limiting Toxicities (DLT).

Pharmacokinetics (PK): Peak Plasma Concentration (Cmax), Area under the plasma concentration
versus time curve (AUC), Time of Maximum Concentration Observed (Tmax).

Efficacy: Overall Response Rate (ORR), Progression Free Survival (PFS); Overall Survival (OS)
and duration of Response (DoR).

Inclusion Criteria:

- Refractory to or relapsed after at least 1 prior treatment line.

- Eastern Cooperative Oncology Group (ECOG) performance status ≤2

- Patients must be ≥18 years of age

- Able to give a written informed consent.

Exclusion Criteria:

- Patients receiving cancer therapy within 3 weeks prior to Cycle1 Day1 (C1D1).

- Patients with active Hepatitis B virus (HBV), Hepatitis C virus (HCV) or Human immune
deficiency virus (HIV) infection

- Patients who received Allo-Stem cell Transplantation(Allo-SCT) within 12 months.

- Patients with graft versus-host disease (GVHD)

- Subjects who have received drugs that directly or indirectly inhibit calcineurin or
Nuclear Factor of activated T cells (NFAT) activity .

- Patient with symptomatic, or history of documented congestive heart failure (NY Heart
Association functional classification III-IV);

- Patient with Frederica's (QTcF) formulas (QTcF) ≥450 msec;

- Patient with angina not well-controlled by medication;

- Women who are pregnant or lactating.